middle.news
Nexalis Screens First Patient in Phase 2 Trial for Breakthrough Cancer Pain
10:32am on Monday 20th of April, 2026 AEST
•
Healthcare
Read Story
Nexalis Screens First Patient in Phase 2 Trial for Breakthrough Cancer Pain
10:32am on Monday 20th of April, 2026 AEST
Key Points
First patient screened in Phase 2 IRX-211 trial for Breakthrough Cancer Pain
Randomised, double-blind, placebo-controlled cross-over study with 156 patients planned
IRX-211 designed as rapid, inhaled therapy for opioid-tolerant cancer patients
Global cancer pain market projected to reach around US$11 billion by 2028
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE